Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Pollen Allergenic Extract [EPC]
Ulmus Rubra Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of allergic diseases. It belongs to the class of pollen allergenic extracts and is primarily utilized in skin testing and subcutaneous immunotherapy.
Name
Ulmus Rubra Pollen
Raw Name
ULMUS RUBRA POLLEN
Category
Non-Standardized Pollen Allergenic Extract [EPC]
Drug Count
4
Variant Count
5
Last Verified
February 17, 2026
About Ulmus Rubra Pollen
Ulmus Rubra Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of allergic diseases. It belongs to the class of pollen allergenic extracts and is primarily utilized in skin testing and subcutaneous immunotherapy.
Detailed information about Ulmus Rubra Pollen
References used for this content
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Ulmus Rubra Pollen.
Ulmus Rubra Pollen, derived from the Slippery Elm tree, is a biological substance classified as a Non-Standardized Pollen Allergenic Extract [EPC]. In the realm of clinical immunology, this extract is utilized as both a diagnostic tool and a therapeutic agent. Unlike standardized extracts that have a defined potency (such as Bioequivalent Allergy Units), Ulmus Rubra Pollen is typically measured in Weight/Volume (w/v) or Protein Nitrogen Units (PNU). This substance belongs to a broader class of drugs known as allergenic extracts, which are designed to interact with the human immune system to either identify specific sensitivities or induce immunological tolerance.
According to the FDA-approved labeling for allergenic extracts, these products have been used for over a century to manage allergic rhinitis (hay fever) and allergic asthma. Ulmus Rubra, specifically, is a deciduous tree native to eastern North America. Its pollen is a significant aeroallergen during the spring months. The pharmacological preparation involves the extraction of allergenic proteins from the raw pollen grains, which are then stabilized in a solution of glycerin or phenol-preserved saline. This extract is primarily indicated for patients who exhibit symptoms of Type I immediate hypersensitivity reactions when exposed to elm tree pollen.
The mechanism of action for Ulmus Rubra Pollen depends on its application. In diagnostic skin testing, the extract is introduced into the epidermis or dermis. If the patient has pre-existing IgE (Immunoglobulin E) antibodies specific to Ulmus Rubra, these antibodies—which are bound to mast cells—will cross-link upon contact with the pollen proteins. This triggers mast cell degranulation, releasing histamine and other inflammatory mediators, resulting in a "wheal and flare" reaction (a raised bump and surrounding redness). This serves as a clinical confirmation of the patient's allergic sensitivity.
In the context of Allergen Immunotherapy (AIT), the mechanism is more complex and involves a fundamental shift in the immune system's response. When administered through regular subcutaneous injections (allergy shots), the extract works by inducing "desensitization" or "hyposensitization." At the molecular level, this involves:
Unlike traditional small-molecule drugs, the pharmacokinetics of allergenic extracts like Ulmus Rubra Pollen are not characterized by traditional absorption, distribution, metabolism, and excretion (ADME) studies.
Ulmus Rubra Pollen extract is FDA-approved for the following indications:
Ulmus Rubra Pollen is available in the following formulations:
> Important: Only your healthcare provider can determine if Ulmus Rubra Pollen is right for your specific condition. The selection of the appropriate concentration and dosing schedule must be individualized based on the patient's clinical history and sensitivity levels.
Dosage for Ulmus Rubra Pollen is highly individualized and does not follow a "one size fits all" approach. The dosing is divided into two distinct phases: the Build-up (Escalation) Phase and the Maintenance Phase.
During this phase, the patient receives increasing concentrations of the extract. Typically, injections are administered 1 to 2 times per week. The starting dose is usually 0.05 mL of a very dilute solution (e.g., 1:100,000 w/v or 1:10,000 w/v), depending on the patient's skin test reactivity. The dose is gradually increased until the maintenance dose is reached, which usually takes 3 to 6 months.
Once the effective dose is reached, the frequency of injections is decreased to once every 2 to 4 weeks. A common maintenance dose ranges from 0.2 mL to 0.5 mL of the most concentrated extract (e.g., 1:10 or 1:20 w/v). The goal is to maintain the highest dose that the patient tolerates without significant local or systemic side effects.
Ulmus Rubra Pollen is generally considered safe for pediatric use; however, it is rarely initiated in children under the age of 5 due to the difficulty of monitoring for systemic reactions and the child's ability to communicate symptoms of anaphylaxis. The dosing schedule for children is similar to adults but may be adjusted based on the child's body mass and the severity of their allergic disease. Healthcare providers often use a more conservative build-up schedule for pediatric patients.
No specific dosage adjustments are required for patients with renal impairment, as the extract is not cleared via the kidneys. However, the patient's overall health and ability to tolerate a potential systemic reaction must be considered.
No dosage adjustments are necessary for hepatic impairment. The metabolism of allergenic proteins is independent of liver function.
Elderly patients (over 65) should be evaluated carefully. While there is no specific age-related dose adjustment, the presence of cardiovascular disease or the use of beta-blockers (which are more common in this demographic) may increase the risks associated with immunotherapy.
Ulmus Rubra Pollen must only be administered by a healthcare professional trained in the management of allergic diseases and equipped to handle anaphylaxis.
If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated to ensure safety. If a dose is missed during the maintenance phase for more than 4-6 weeks, the dose is typically reduced by one or two increments. Your allergist will follow a specific "missed dose protocol" to safely get you back on schedule.
An overdose of Ulmus Rubra Pollen occurs if a patient receives a higher concentration than scheduled or if the injection is accidentally administered intravenously. Signs of overdose include immediate systemic reactions, such as generalized hives, swelling of the throat, wheezing, and a drop in blood pressure. Treatment involves immediate administration of epinephrine (1:1000) and emergency supportive care.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip appointments without medical guidance, as this increases the risk of adverse reactions.
Local reactions are the most common side effect of Ulmus Rubra Pollen injections. These occur at the site of the injection and are generally considered a normal part of the immune response.
> Warning: Stop taking Ulmus Rubra Pollen and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis.
There are no known long-term detrimental effects of Ulmus Rubra Pollen when used according to established protocols. In fact, the "long-term effect" is intended to be beneficial—a permanent or semi-permanent reduction in allergic sensitivity. However, some patients may develop a persistent sensitivity to the injection process itself, known as "needle phobia," or may experience localized skin changes at the site of repeated injections over several years.
Allergenic extracts, including Ulmus Rubra Pollen, carry a significant FDA-mandated warning regarding the risk of severe systemic reactions.
Report any unusual symptoms to your healthcare provider immediately, even if they occur several hours after leaving the clinic.
Ulmus Rubra Pollen is a potent biological agent. Its use is restricted to patients with a documented history of allergy where environmental triggers cannot be avoided. It is not a "cure" for allergies but a long-term management strategy. Patients must be committed to the schedule, as irregular dosing significantly increases the risk of adverse events.
No FDA black box warnings specifically for Ulmus Rubra Pollen exist as a unique entity, but it falls under the mandatory class-wide warning for all Allergenic Extracts. This warning emphasizes that these products are intended for use only by physicians experienced in administering allergenic extracts and that they can cause severe, life-threatening anaphylaxis. Patients with severe or unstable asthma are at higher risk for fatal reactions.
While Ulmus Rubra Pollen does not typically cause sedation, a systemic reaction or the administration of emergency medications (like antihistamines or epinephrine) can impair your ability to drive. It is generally advised to wait until the 30-minute observation period is over and you feel completely normal before operating a vehicle.
Alcohol consumption should be avoided for several hours before and after an injection. Alcohol can cause vasodilation (widening of blood vessels), which may theoretically speed up the absorption of the allergen or mask the early signs of a systemic reaction.
Immunotherapy is typically discontinued after 3 to 5 years of successful treatment. There is no "withdrawal syndrome" associated with stopping Ulmus Rubra Pollen, but your allergy symptoms may gradually return if the immune system has not fully transitioned to a state of tolerance. Tapering is not pharmacologically necessary, but the decision to stop should be a joint one between the patient and the allergist.
> Important: Discuss all your medical conditions, especially any heart or lung problems, with your healthcare provider before starting Ulmus Rubra Pollen.
There are no direct food interactions with Ulmus Rubra Pollen. However, patients with "Oral Allergy Syndrome" (Pollen-Food Allergy Syndrome) may find that their sensitivity to certain fruits (like stone fruits) increases temporarily during the build-up phase of their elm pollen shots. This is due to cross-reactivity between the pollen proteins and similar proteins in the food.
For each major interaction, the primary concern is the management of anaphylaxis. The mechanism is usually pharmacodynamic (affecting the body's response to the drug or the rescue medication) rather than pharmacokinetic (affecting drug levels).
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for blood pressure or heart rhythm.
There are several conditions where Ulmus Rubra Pollen must NEVER be used:
Conditions requiring a careful risk-benefit analysis include:
Patients allergic to Ulmus Rubra (Slippery Elm) often show cross-sensitivity to other members of the Ulmaceae family, such as Ulmus Americana (American Elm). If you are allergic to one species of elm, you are likely allergic to others. There is also minor cross-reactivity noted with certain members of the Cannabaceae family (like Hackberry) due to shared protein structures.
> Important: Your healthcare provider will evaluate your complete medical history and current health status before prescribing Ulmus Rubra Pollen.
Ulmus Rubra Pollen is classified as Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether the extract can cause fetal harm. The primary risk during pregnancy is not the extract itself, but the potential for a systemic reaction (anaphylaxis) in the mother. Anaphylaxis can lead to a sudden drop in blood pressure and uterine contraction, which can cause fetal hypoxia (lack of oxygen) or miscarriage.
It is not known whether the allergenic components of Ulmus Rubra Pollen are excreted in human milk. However, because these are large protein molecules that are typically degraded at the injection site or in the lymphatic system, the risk to a nursing infant is considered negligible. Breastfeeding is not a contraindication for continuing immunotherapy.
As previously noted, Ulmus Rubra Pollen is effective in children, but caution is warranted. The American Academy of Allergy, Asthma & Immunology (AAAAI) suggests that the benefits of preventing the "allergic march" (the progression from hay fever to asthma) often outweigh the risks in children over age 5. Dosing must be meticulously monitored, and the child must be able to sit still for the injection and the 30-minute observation period.
In patients over 65, the decision to use Ulmus Rubra Pollen must account for the higher prevalence of underlying cardiovascular disease. The elderly are more likely to be taking medications like beta-blockers or ACE inhibitors, which complicate the safety profile. Furthermore, the physiological reserve to survive a severe anaphylactic event is often reduced in this population.
No dosage adjustments are needed. The allergenic proteins do not rely on renal filtration for clearance. However, patients with chronic kidney disease should be monitored for overall fluid balance and cardiovascular stability if a systemic reaction occurs.
No dosage adjustments are needed for patients with liver disease. The processing of allergens occurs via the immune system and local proteolysis, not the hepatic cytochrome P450 system.
> Important: Special populations require individualized medical assessment and a more cautious approach to dosing and monitoring.
Ulmus Rubra Pollen acts as an immunomodulator. Its primary molecular target is the interaction between the Antigen-Presenting Cells (APCs), such as dendritic cells, and T-lymphocytes. In an allergic individual, these cells promote a Th2-biased response, leading to IgE production. Immunotherapy with Ulmus Rubra Pollen forces the immune system to recognize the allergen in a non-inflammatory context. This leads to the production of IL-10-producing Regulatory T-cells (Tregs). These Tregs then signal B-cells to switch from IgE production to IgG4 production. IgG4 acts as a "decoy" or "blocking" antibody, binding to the elm pollen proteins before they can reach the IgE on the surface of mast cells.
The dose-response relationship in immunotherapy is characterized by a "threshold effect." Small doses may have no effect, while reaching a specific "maintenance level" is required to see clinical improvement. The time to onset is slow; patients typically do not see symptom relief until they have been on the maintenance dose for several months. The duration of effect can be long-lasting, often persisting for years after the 3-5 year treatment course is completed.
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Subcutaneous) |
| Protein Binding | N/A (Proteins are the drug) |
| Half-life | Variable (Hours at site; days for immune effect) |
| Tmax | 1-2 hours (Local absorption) |
| Metabolism | Local and systemic proteolysis |
| Excretion | Catabolic amino acid pathways |
Ulmus Rubra Pollen is classified as a Non-Standardized Pollen Allergenic Extract. It is related to other tree pollen extracts such as Oak, Maple, and Birch. While they share the same therapeutic class, they are not interchangeable; a patient must be treated with the specific pollen to which they are allergic.
Common questions about Ulmus Rubra Pollen
Ulmus Rubra Pollen extract is primarily used for the diagnosis and treatment of seasonal allergies caused by the Slippery Elm tree. In diagnostic settings, it is used in skin prick tests to identify if a patient has a specific IgE-mediated sensitivity to this pollen. For treatment, it is used in allergen immunotherapy, commonly known as allergy shots, to help the body build a tolerance to the allergen over time. This can significantly reduce symptoms like sneezing, itchy eyes, and nasal congestion. It is especially helpful for patients who do not get enough relief from standard over-the-counter allergy medications.
The most frequent side effects are localized reactions at the site of the injection, occurring in nearly all patients at some point during treatment. These include redness, swelling, itching, and a firm bump (wheal) where the needle entered the skin. These symptoms usually appear within minutes and resolve within a few hours to a day. Some patients may also experience mild fatigue or a headache following their appointment. While bothersome, these local reactions are generally not dangerous and can be managed with ice packs or simple antihistamines. However, any reaction that spreads or causes difficulty breathing must be reported immediately.
It is strongly recommended to avoid alcohol consumption on the days you receive your Ulmus Rubra Pollen injections. Alcohol can cause your blood vessels to dilate, which might increase the speed at which the allergen is absorbed into your bloodstream, potentially raising the risk of a systemic reaction. Additionally, alcohol can mask the early symptoms of anaphylaxis, such as feeling flushed or dizzy, making it harder for you or your doctor to recognize a medical emergency. To ensure the highest level of safety, wait at least 24 hours after your injection before consuming alcoholic beverages. Always discuss your lifestyle habits with your allergist.
The safety of starting Ulmus Rubra Pollen immunotherapy during pregnancy has not been established, and it is generally avoided. The main concern is not that the extract will harm the baby directly, but that a severe allergic reaction in the mother could lead to a drop in oxygen for the fetus. However, if a woman is already on a stable maintenance dose and becomes pregnant, most doctors will continue the treatment because the risk of a reaction is much lower at that stage. Stopping the treatment could also cause an increase in asthma symptoms, which is also risky for the pregnancy. Every case must be evaluated individually by an allergy specialist.
Immunotherapy with Ulmus Rubra Pollen is a slow process that requires patience, as it involves retraining the immune system at a cellular level. Most patients do not notice a significant improvement in their allergy symptoms during the initial 'build-up' phase, which lasts three to six months. Significant relief typically begins only after the patient has reached their maintenance dose and has been on it for several months. For the best results, the treatment usually continues for three to five years. If no improvement is seen after one full year of maintenance therapy, your doctor may re-evaluate the treatment plan.
Yes, you can stop taking Ulmus Rubra Pollen injections suddenly without experiencing physical withdrawal symptoms, as it is not an addictive or physiologically dependent medication. However, stopping the treatment before the recommended three-to-five-year period significantly increases the chance that your allergy symptoms will return. The immune system needs consistent, long-term exposure to the pollen extract to maintain the state of tolerance. If you need to stop treatment due to side effects or life changes, discuss it with your allergist first. They can help you determine if a different schedule or a different type of treatment might be better for you.
If you miss a dose of Ulmus Rubra Pollen, you should contact your allergist's office as soon as possible to reschedule. Do not attempt to 'double up' on your next dose or take an injection at home. Depending on how long it has been since your last shot, your doctor may need to reduce your next dose slightly to ensure your safety. This is because your level of tolerance can drop if too much time passes between injections. Following the specific missed-dose protocol provided by your healthcare team is essential for preventing a systemic reaction when you resume treatment.
There is no scientific evidence or clinical data suggesting that Ulmus Rubra Pollen allergenic extracts cause weight gain. Unlike systemic corticosteroids (like prednisone), which are sometimes used to treat severe allergies and can cause weight changes, allergenic extracts are proteins that work locally and through the lymphatic system. They do not affect your metabolism, appetite, or fat distribution. If you experience weight gain while undergoing immunotherapy, it is likely due to other factors, such as lifestyle changes or other medications you may be taking, and you should discuss this with your primary care physician.
Ulmus Rubra Pollen can be taken with most standard medications, but there are critical exceptions. You must inform your doctor if you are taking beta-blockers, ACE inhibitors, or certain antidepressants (MAOIs), as these can make an allergic reaction much more dangerous or harder to treat. Most common allergy medications, like antihistamines and nasal sprays, are perfectly safe and are often used alongside the injections to manage symptoms during the build-up phase. Always provide your allergist with a complete and updated list of all prescriptions, over-the-counter drugs, and herbal supplements you are currently using.
In the world of allergenic extracts, the term 'generic' is not used in the same way as it is for tablets like ibuprofen. Instead, multiple biological manufacturers (such as Greer, Antigen Laboratories, or HollisterStier) produce their own versions of Ulmus Rubra Pollen extract. While these products are essentially the same biological material, they are not considered identical because they are non-standardized. Your allergist will typically stick with one manufacturer's extract for the duration of your treatment to ensure consistency in potency and to minimize the risk of a reaction that could occur when switching between different brands.